The latest price and medical insurance policy of larotinib/larlotinib in 2025

Larotrectinib As a precision targeted therapy drug that specifically targets solid tumors withNTRK gene fusion, it has attracted widespread attention in domestic and foreign markets. It has been approved by the National Medical Products Administration (NMPA) for marketing in China and has been included in the National Medical Insurance List, which is a major development in the field of targeted treatment of rare tumors. Currently, larotrectinib has two common specifications in the Chinese market. One is a capsule preparation of 100 mg and 56 capsules, with a market price of about 20,000 yuan; the other is an oral solution in a 50ml:1.0g2 bottle, priced at about 7,000 yuan. The specific price may vary slightly depending on regional medical insurance reimbursement ratios and hospital procurement policies.

After larotinib was included in medical insurance, patients’ actual medication costs dropped significantly. Especially for NTRK fusion mutations, a relatively rare but clear target, the drug is highly precise and provides new hope for patients who are ineffective in other treatments. At present, medical insurance payment is mainly based on the positioning of drugs in targeted tumor treatment. Reimbursement policies and proportions may be different in different regions. Patients should consult the local hospital pharmacy or medical insurance bureau for the latest information before use. Generally speaking, the price after reimbursement by medical insurance can be reduced to several thousand yuan or even lower, which greatly alleviates the financial pressure of medication.

In the international market, especially in European and American countries, the price of larotrectinib is still at a relatively high level, with some specifications selling for thousands of dollars per month. At the same time, as market demand grows, some Asian countries such as Laos and India have begun to launch generic pharmaceutical products of larotrectinib. On the basis that the chemical composition of these generic drugs is consistent with that of the original drugs, they have passed bioequivalence testing and strive to achieve similar efficacy. For example, the generic version of larotrectinib produced in Laos may cost only a few hundred to one thousand yuan in capsule form with the same specifications, providing an alternative for patients who cannot afford the price of the original drug.

Reference materials:https://www.vitrakvi.com/